Atrial fibrillation (AF) is a widespread heart rhythm disorder that can lead to blood clots and strokes. Catheter ablation has shown promise as a treatment for AF, but conventional methods using heat or cold can cause serious complications.
Pulsed Field Ablation (PFA) is an innovative technology that offers a safer and more effective alternative. Unlike traditional therapies, PFA uses non-thermal electric fields to precisely ablate heart tissue in a matter of seconds. This tissue-selective approach leads to faster and more durable clinical outcomes for patients.
CathRx has developed a state-of-the-art PFA generator and integrated it with a globally recognised catheter system, setting a new standard in the field. Successful preclinical studies have demonstrated the safety and effectiveness of this combined system, paving the way for First in Human clinical trials. This milestone brings us closer to validating and introducing this cutting-edge medical technology to the world.
Thanks to the CTCM grant, CathRx’s clinical program has been accelerated, allowing us to establish the safety and effectiveness of Australia’s pioneering PFA system. By collecting essential data to support regulatory approval, this program expedites the commercialisation process, significantly reducing the timeline compared to without CTCM funding.
CTCM Project Round: Two
State: New South Wales
Project Partner:
Funding:
Duration: September 2023 – June 2025
Website: CathRx Ltd | LinkedIn: Cath CathRx Limited
Twitter: @CathrxL
